Loading...
Please wait, while we are loading the content...
Circulating biomarkers of bevacizumab activity in patients with breast cancer
| Content Provider | Scilit |
|---|---|
| Author | Denduluri, Neelima Yang, Sherry X. Berman, Arlene W. Nguyen, Diana Liewehr, David J. Steinberg, Seth M. Swain, Sandra M. |
| Copyright Year | 2008 |
| Description | Purpose: Noninvasive markers of anti-vascular endothelial growth factor (VEGF) therapy are needed. Soluble vascular cell adhesion molecule (sVCAM-1), soluble VEGF receptor-2 (sVEGFR-2), and plasma VEGF levels were assessed as potential biomarkers of therapy with bevacizumab. Tumor samples were evaluated for VEGFR-2 mutations before and after bevacizumab.Experimental Design: Twenty-one patients with breast cancer underwent neoadjuvant treatment with bevacizumab for 1 cycle followed by 6 cycles of bevacizumab, chemotherapy, and filgrastim. Peripheral blood samples were collected at baseline, post cycles 1, 4 and 7. sVCAM-1, VEGF and sVEGFR-2 levels were measured by enzyme-linked immunosorbent assay (ELISA). Exons 17-26 of VEGFR-2 were sequenced on tissue samples from 20 patients at baseline and post cycle 1 to evaluate for tumor mutations.Results: From baseline to post cycle 1, sVCAM-1 and sVEGFR-2 values increased by a median of 180.5 ng/ml (p |
| Related Links | https://www.tandfonline.com/doi/pdf/10.4161/cbt.7.1.5337?needAccess=true |
| Ending Page | 20 |
| Page Count | 6 |
| Starting Page | 15 |
| ISSN | 15384047 |
| e-ISSN | 15558576 |
| DOI | 10.4161/cbt.7.1.5337 |
| Journal | Cancer Biology & Therapy |
| Issue Number | 1 |
| Volume Number | 7 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2008-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Cancer Biology & Therapy Medical Laboratory Technology Bevacizumab Svcam Vascular Soluble Treatment Svegfr Biomarkers Breast |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Pharmacology Molecular Medicine Oncology |
